<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409458</url>
  </required_header>
  <id_info>
    <org_study_id>PT-112-103-PAVE-1</org_study_id>
    <nct_id>NCT03409458</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab</brief_title>
  <acronym>PAVE-1</acronym>
  <official_title>A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phosplatin Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phosplatin Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2a, open-label, multi-center, non-randomized, dose-escalation study of&#xD;
      PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid&#xD;
      tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within&#xD;
      the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer&#xD;
      who will be treated at the RP2D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2a, open-label, multi-center, non-randomized, dose-escalation study of&#xD;
      PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid&#xD;
      tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within&#xD;
      the combination and the Dose Confirmation Phase. The Dose Escalation Phase will determine the&#xD;
      Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D) of PT-112 in the combination&#xD;
      with avelumab, and will evaluate the PK, safety and tolerability, and efficacy. The Dose&#xD;
      Confirmation Phase will evaluate patients with non-small cell lung cancer who will be treated&#xD;
      at the RP2D.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose (RD) of PT-112 to be used in combination with avelumab for further studies in patients with advanced solid tumors.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma concentration (Cmax) for PT-112 Injection</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for PT-112 Injection</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events (AEs)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor burden Assessment</measure>
    <time_frame>24 months</time_frame>
    <description>To be assessed by iRECIST criteria for NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival (mPFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>PT-112 in combination with avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion&#xD;
Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT-112</intervention_name>
    <description>The MTD and RP2D of PT-112 when used in combination with avelumab will be determined during dose escalation.</description>
    <arm_group_label>PT-112 in combination with avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>avelumab</intervention_name>
    <description>Avelumab will be administered at a fixed dose of 800 mg.</description>
    <arm_group_label>PT-112 in combination with avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven metastatic or locally advanced disease.&#xD;
             Specifically:&#xD;
&#xD;
             -patients with NSCLC, must have measurable disease by RECIST v1.1 criteria&#xD;
&#xD;
          2. Must provide study-related tumor specimens;&#xD;
&#xD;
          3. ECOG(PS) 0-1;&#xD;
&#xD;
          4. Estimated Life Expectancy &gt; 3 months;&#xD;
&#xD;
          5. Adequate bone marrow (BM), renal, hepatic and metabolic function.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine&#xD;
             therapy, cytotoxic agents, targeted small molecule therapy or any investigational&#xD;
             anticancer small molecule drugs within 2 weeks prior to the start of study treatment&#xD;
             (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal&#xD;
             antibodies within 4 weeks prior to the start of study treatment;&#xD;
&#xD;
          2. Known symptomatic central nervous system (CNS) metastases requiring steroids.&#xD;
&#xD;
          3. Diagnosis of any other malignancy within 2 years prior to enrollment;&#xD;
&#xD;
          4. Vaccination within 4 weeks of the first dose of study treatment is prohibited except&#xD;
             for administration of inactivated vaccines;&#xD;
&#xD;
          5. Current use of immunosuppressive medication at study entry;&#xD;
&#xD;
          6. Active or prior autoimmune disease that might deteriorate with receiving an&#xD;
             immunostimulatory agent;&#xD;
&#xD;
          7. Acute or chronic infections requiring systemic therapy;&#xD;
&#xD;
          8. Known history of autoimmune colitis, inflammatory bowel disease, pneumonitis,&#xD;
             pulmonary fibrosis;&#xD;
&#xD;
          9. Known intolerance to checkpoint inhibitor therapy, defined by the occurrence of an AE&#xD;
             leading to drug discontinuation;&#xD;
&#xD;
         10. Participation in other studies involving investigational drug(s) within 28 days prior&#xD;
             to study entry and/or during study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel D Karp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Summa</last_name>
    <phone>(617) 335-1794</phone>
    <email>jsumma@phosplatin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariam Mahbob</last_name>
    <email>mmahbob@phosplatin.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel D. Karp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

